Investigational Drug Information for GS-9674
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for GS-9674?
GS-9674 is an investigational drug.
There have been 11 clinical trials for GS-9674.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 27th 2019.
The most common disease conditions in clinical trials are Fatty Liver, Non-alcoholic Fatty Liver Disease, and Cholangitis. The leading clinical trial sponsors are Gilead Sciences, Novo Nordisk A/S, and [disabled in preview].
There are eight US patents protecting this investigational drug and one hundred and twenty-seven international patents.
Summary for GS-9674
| US Patents | 8 |
| International Patents | 127 |
| US Patent Applications | 19 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-03-27) |
| Vendors | 25 |
Recent Clinical Trials for GS-9674
| Title | Sponsor | Phase |
|---|---|---|
| Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) | Novo Nordisk A/S | Phase 2 |
| Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) | Gilead Sciences | Phase 2 |
| Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis | Gilead Sciences | Phase 1 |
Clinical Trial Summary for GS-9674
Top disease conditions for GS-9674
Top clinical trial sponsors for GS-9674
US Patents for GS-9674
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GS-9674 | See Plans and Pricing | FXR agonists and methods for making and using | Salk Institute for Biological Studies (La Jolla, CA) | See Plans and Pricing |
| GS-9674 | See Plans and Pricing | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (Foster City, CA) | See Plans and Pricing |
| GS-9674 | See Plans and Pricing | FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. (Foster City, CA) | See Plans and Pricing |
| GS-9674 | See Plans and Pricing | Acyclic antivirals | Janssen BioPharma, Inc. (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GS-9674
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GS-9674 | Australia | AU2015229072 | 2034-03-13 | See Plans and Pricing |
| GS-9674 | Canada | CA2942403 | 2034-03-13 | See Plans and Pricing |
| GS-9674 | European Patent Office | EP3116878 | 2034-03-13 | See Plans and Pricing |
| GS-9674 | Japan | JP2017510572 | 2034-03-13 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
